BioELife Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BioELife has 9.41 million shares outstanding.
| Current Share Class | 9.41M |
| Shares Outstanding | 9.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +78.22% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.14 |
| P/TBV Ratio | 0.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.54
| Current Ratio | 0.54 |
| Quick Ratio | 0.54 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.14 |
Financial Efficiency
Return on equity (ROE) is -598.11% and return on invested capital (ROIC) is -24.00%.
| Return on Equity (ROE) | -598.11% |
| Return on Assets (ROA) | -16.48% |
| Return on Invested Capital (ROIC) | -24.00% |
| Return on Capital Employed (ROCE) | -1,313.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -589,687 |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9,900.00% in the last 52 weeks. The beta is -39.32, so BioELife's price volatility has been lower than the market average.
| Beta (5Y) | -39.32 |
| 52-Week Price Change | +9,900.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 54.47 |
| Average Volume (20 Days) | 1,112 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | -800 |
| Operating Income | -90,993 |
| Pretax Income | -589,687 |
| Net Income | -589,687 |
| EBITDA | n/a |
| EBIT | -90,993 |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 22,247 in cash and n/a in debt, giving a net cash position of 22,247 or 0.00 per share.
| Cash & Cash Equivalents | 22,247 |
| Total Debt | n/a |
| Net Cash | 22,247 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 6,927 |
| Book Value Per Share | 0.00 |
| Working Capital | -18,707 |
Cash Flow
In the last 12 months, operating cash flow was -116,037 and capital expenditures -12,064, giving a free cash flow of -128,101.
| Operating Cash Flow | -116,037 |
| Capital Expenditures | -12,064 |
| Free Cash Flow | -128,101 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioELife does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.70% |
| Shareholder Yield | -33.70% |
| Earnings Yield | -62,665.99% |
| FCF Yield | -13,613.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 4, 2018. It was a reverse split with a ratio of 0.025.
| Last Split Date | Dec 4, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |